Combinational Therapy Enhances the Effects of Anti-Igf-1r mAb Figitumumab to Target Small Cell Lung Cancer

PLoS ONE- United States

doi 10.1371/journal.pone.0135844

Full Text

Abstract

Available in

Date

Authors

Publisher

Public Library of Science (PLoS)

Related search

IGF-1R as an Anti-Cancer Target--Trials and Tribulations

Chinese Journal of Cancer
2013English

Novel Carbonic Anhydrase IX-targeted Therapy Enhances the Anti-Tumour Effects of Cisplatin in Small Cell Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Revisiting the IGF-1R as a Breast Cancer Target

npj Precision Oncology
2017English

How to Target Small Cell Lung Cancer

Oncoscience
Cancer ResearchOncology
2015English

Safety, Tolerability, and Pharmacokinetics of the Anti-Igf-1r Monoclonal Antibody Figitumumab in Patients With Refractory Adrenocortical Carcinoma

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2009English

Newly Developed Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer

Oncotarget
Oncology
2017English

Vorinostat Enhances the Cisplatin-Mediated Anticancer Effects in Small Cell Lung Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Can We Unlock the Potential of IGF-1R Inhibition in Cancer Therapy?

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2014English

Molecular Imaging of IGF-1R in Cancer

Molecular Imaging
Nuclear MedicineRadiologyMolecular MedicineCondensed Matter PhysicsImagingBiotechnologyBiomedical Engineering
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy